



March 13, 2014

Integra LifeSciences Announces First Implantation of Integra(R) Laminoplasty System

PLAINSBORO, N.J., March 13, 2014 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the first implantation of its Integra® Laminoplasty System, in the United States. The system, which is used to treat patients with ossification of the posterior longitudinal ligament, cervical myelopathy and degenerative spinal canal stenosis, was implanted by Douglas Orndorff, M.D., Orthopaedic Spine Surgeon at the Mercy Medical Center in Durango, Colorado.

"Integra's Laminoplasty system provides surgeons with a versatile solution for treatment of central canal stenosis," said Dr. Orndorff. "The patient presented with progressive cervical myelopathy, had lordotic cervical alignment, and no neck pain. She was the ideal candidate for this laminoplasty procedure."

"The instrumentation was easy to work with and allowed for predictable placement of the plate and screws," continued Dr. Orndorff. "The plate's arched radius is ideal for spinal canal expansion, and the foot on the plate provided effective initial stability. It is also possible to contour and trim the plate to accommodate variable patient anatomy."

The Laminoplasty System is designed for use after open-door laminoplasty procedures in the cervical and thoracic spine (C3-T3). The system encompasses a variety of robust, arched plate designs, self-drilling bone screws and multiple insertion options, offering surgeons choices when treating patients with central canal stenosis and myelopathy.

"The Integra Laminoplasty system complements and expands our posterior cervical portfolio and offers surgeons an anatomic solution for laminoplasty procedures. We look forward to continued success and growth in this market," said Brian Larkin, President-Spine.

The global laminoplasty market is estimated to reach approximately \$70 million by 2015. With the addition of the Laminoplasty System, Integra is well positioned to gain a key foothold in this rapidly growing market.

Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. For more information, please visit www.integralife.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2013 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences:

Media

Gianna Sabella

609-936-2389

gianna.sabella@integralife.com

Investors

Angela Steinway

609-936-2268

angela.steinway@integralife.com